1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Oculis Looks To Move Dry Eye Candidate To Phase III Despite Mixed Dataset

 
• By Joseph Haas

Oculis’s licaminlimab showed ability to treat a sign of dry eye disease in a genetic subpopulation, but data in the fuller Phase IIb trial enrollment were less impressive.

Dry eye disease
Oculis thinks its candidate can benefit a genetic subset of dry eye patients • Source: Shutterstock

Oculis S.A. missed statistical significance in most signs of dry eye disease in the 122-patient RELIEF study of licaminlimab (OCS-2), but the trial did reach statistical significance in a biomarker-identified subgroup on one sign of the disease, corneal inflammation, and the company believes that the positive trends overall support moving into Phase III.

Key Takeaways

  • Oculis is planning to target inflammation and apoptosis in dry eye disease with its novel anti-TNFα eye drop licaminlimab.

During a same-day call, Oculis CEO Riad Sherif talked about convening an end-of-Phase II meeting with the US Food and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.